A Randomized Trial of Anticoagulation Strategies in COVID-19:PROTECT-COVID 19

Brief description of study

Anticoagulation medicines are used to reduce the risk of blood clot formation in the blood vessels. Blood clots that form in blood vessels can travel in the blood vessels and block the blood flow to body organs. Anticoagulation medicines can be given in lower doses to prevent blood clot formation, or higher doses to treat blood clots that have already formed. Anticoagulation drugs are used to prevent the risk of blood clot formation in patients in the hospital due to COVID-19 infection, but the optimal dose of the anticoagulation drugs is not known. The purpose of the study is to compare a lower dose against a higher dose to reduce complications of blood clot formation in patients who are in the hospital due to COVID-19 infection. The drugs used in both regimens, heparin and enoxaparin, are Food and Drug Administration (FDA) approved for preventing clotting events.


Clinical Study Identifier: s20-00479
ClinicalTrials.gov Identifier: NCT04359277


If you are registered as a volunteer, please login to the dashboard to send referrals.